Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Rosetta licenses PCR tech
January 2008
SHARING OPTIONS:

REHOVOT, Israel—Rosetta Genomics' wholly owned subsidiary, Rosetta Genomics Inc., now has a license from Roche Molecular Systems to use its PCR technology in miRNA-based diagnostic tests. Rosetta Genomics has developed a custom-designed, highly sensitive and specific mRNA detection platform which is based on Roche PCR technology. This proprietary platform allows Rosetta Genomics to identify miRNA biomarkers in several sample types and body fluids, with very high sensitivity and specificity.

"Based on the PCR platform, as well as other proprietary technologies, we are developing a line of highly sensitive microRNA-based products, three of which we expect will launch in 2008," reveals Amir Avniel, president and CEO of Rosetta Genomics. "[We look] forward to the launch of our first microRNA-based diagnostic tests in 2008."

 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.